

ASX Announcement

Results of Annual General Meeting

Sydney, Australia, 30 November 2023: Imugene Limited (ASX:IMU) (Imugene, or the Company) provides the following information in relation to the resolutions put to the shareholders of Imugene at the Annual General Meeting today at 3:00pm (**Meeting**).

All resolutions were passed and decided by way of a poll.

In accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the *Corporations Act 2001* a summary of the proxy votes received and poll results on each Resolution is attached.

Release approved by the Company Secretary on behalf of the Board.

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au

Follow us on Twitter and Instagram @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited
Watch us on YouTube @ImugeneLimited



About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Disclosure of Proxy Votes

Imugene Limited

Annual General Meeting
Thursday, 30 November 2023



Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Directors' Remuneration Report	P	2,081,179,811	1,583,817,962 76.10%	449,208,761 21.58%	199,922,231	48,153,088 2.31%	1,630,587,578 78.40%	449,136,878 21.60%	203,046,128	Passed
2 Election of Director - Ms Kim Drapkin	P	2,399,627,587	2,222,428,957 92.62%	129,090,936 5.38%	23,605,673	48,107,694 2.00%	2,276,716,589 94.59%	130,122,540 5.41%	25,062,673	Passed
3 Approval of amended Employee Share Option Plan	P	2,027,638,731	1,607,360,435 79.27%	375,772,631 18.53%	213,600,796	44,505,665 2.19%	1,647,799,685 81.20%	381,506,223 18.80%	213,602,161	Passed
4 Issue of performance rights to Director - Mr Paul Hopper	P	2,194,275,520	1,592,703,012 72.58%	562,618,012 25.64%	228,957,741	38,954,496 1.78%	1,639,256,435 74.43%	563,053,699 25.57%	229,591,669	Passed
5 Issue of performance rights to Director - Ms Leslie Chong	P	2,391,305,715	1,937,884,099 81.04%	409,484,656 17.12%	31,927,545	43,936,960 1.84%	1,983,105,679 82.65%	416,234,650 17.35%	32,561,473	Passed
6 Issue of restricted stock units to Director - Dr Jakob Dupont	P	2,376,098,875	1,882,552,867 79.23%	449,078,258 18.90%	47,134,385	44,467,750 1.87%	1,932,342,555 81.03%	452,424,862 18.97%	47,134,385	Passed
7 Issue of restricted stock units to Director - Dr Jens Eckstein	P	2,363,278,244	1,841,824,290 77.94%	476,986,204 20.18%	59,955,016	44,467,750 1.88%	1,891,613,978 79.75%	480,332,808 20.25%	59,955,016	Passed
8 Issue of restricted stock units to Director - Dr Lesley Russell	P	2,376,238,696	1,860,325,233 78.29%	471,445,713 19.84%	46,994,564	44,467,750 1.87%	1,909,727,933 80.08%	475,179,305 19.92%	46,994,564	Passed



			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Issue of restricted stock units to Director - Ms Kim Drapkin	P	2,027,277,245	1,558,587,702 76.88%	424,221,793 20.93%	49,842,604	44,467,750 2.19%	1,602,577,390 78.99%	426,368,397 21.01%	49,842,604	Passed
10 Contingent resolution to spill the Board	P	2,365,636,474	198,844,505 8.41%	2,112,087,247 89.28%	57,596,786	54,704,722 2.31%	Resolution Withdrawn			Withdrawn



personal use only